New pill can slow progression of incurable breast cancer. 🧪 www.bbc.co.uk/news/article...
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.co.uk
April 11, 2025 at 4:56 AM
New pill can slow progression of incurable breast cancer. 🧪 www.bbc.co.uk/news/article...
New pill that can slow progression of incurable breast cancer available in the clinic.
Capivasertib combined with hormone therapy doubled the time the cancer took to grow, delaying the need for chemotherapy, & shrank tumours in 23% of patients.
🧪💊
www.bbc.co.uk/news/article...
Capivasertib combined with hormone therapy doubled the time the cancer took to grow, delaying the need for chemotherapy, & shrank tumours in 23% of patients.
🧪💊
www.bbc.co.uk/news/article...
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.co.uk
April 11, 2025 at 8:06 AM
New pill that can slow progression of incurable breast cancer available in the clinic.
Capivasertib combined with hormone therapy doubled the time the cancer took to grow, delaying the need for chemotherapy, & shrank tumours in 23% of patients.
🧪💊
www.bbc.co.uk/news/article...
Capivasertib combined with hormone therapy doubled the time the cancer took to grow, delaying the need for chemotherapy, & shrank tumours in 23% of patients.
🧪💊
www.bbc.co.uk/news/article...
#BBCNews - New pill can slow progression of incurable breast cancer
www.bbc.com/news/article...
#capivasertib
www.bbc.com/news/article...
#capivasertib
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.com
April 11, 2025 at 5:39 AM
#BBCNews - New pill can slow progression of incurable breast cancer
www.bbc.com/news/article...
#capivasertib
www.bbc.com/news/article...
#capivasertib
‘Gamechanging’ breast cancer pill to be offered on NHS in England and Wales
‘Gamechanging’ breast cancer pill to be offered on NHS in England and Wales
U-turn by medicines watchdog means about 3,000 women with advanced forms of disease could benefit each year
Thousands of women with advanced breast cancer in England and Wales are to be offered a “gamechanging” twice-a-day pill on the NHS after a U-turn by the medicines watchdog.
Experts hailed the decision as a “landmark moment”. As many as 3,000 women every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread. Continue reading...
www.theguardian.com
April 10, 2025 at 11:10 PM
‘Gamechanging’ breast cancer pill to be offered on NHS in England and Wales
A new type of drug for one of the most common kinds of advanced breast cancer is now available on the NHS in England.
Some 3,000 women a year could benefit from capivasertib after a clinical trial showed it can slow progression of the disease, and shrink tumours in a quarter of people.
Some 3,000 women a year could benefit from capivasertib after a clinical trial showed it can slow progression of the disease, and shrink tumours in a quarter of people.
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.co.uk
April 11, 2025 at 6:12 AM
A new type of drug for one of the most common kinds of advanced breast cancer is now available on the NHS in England.
Some 3,000 women a year could benefit from capivasertib after a clinical trial showed it can slow progression of the disease, and shrink tumours in a quarter of people.
Some 3,000 women a year could benefit from capivasertib after a clinical trial showed it can slow progression of the disease, and shrink tumours in a quarter of people.
for ~1 in 4 guys with metastatic prostate cancer, treatment wasn't tailored to their pten genetic flaw. but now, fda approved a drug combo that finally targets that specific mutation. that's a really important step from a phase 3 trial.
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for adults with metastatic hormone-sensitive prostate cancer that has a PT
www.fda.gov
June 15, 2026 at 8:02 AM
for ~1 in 4 guys with metastatic prostate cancer, treatment wasn't tailored to their pten genetic flaw. but now, fda approved a drug combo that finally targets that specific mutation. that's a really important step from a phase 3 trial.
www.bbc.co.uk/news/article.... Excellent news for breast cancer patients, based on great work from ICR scientists including our own Nick Turner.
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.co.uk
April 11, 2025 at 5:35 AM
www.bbc.co.uk/news/article.... Excellent news for breast cancer patients, based on great work from ICR scientists including our own Nick Turner.
New pill can slow progression of incurable breast cancer
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.com
April 10, 2025 at 11:06 PM
New pill can slow progression of incurable breast cancer
Menarini Group Unveils Promising Data From Elacestrant and Capivasertib Study at ASCO 2026#Italy#Elacestrant#Florence#Menarini_Group#Capivasertib
Menarini Group Unveils Promising Data From Elacestrant and Capivasertib Study at ASCO 2026
Menarini Group has announced promising early results from the ELEVATE study evaluating elacestrant with capivasertib for ER+, HER2- metastatic breast cancer, showcased at ASCO 2026.
third-news.com
May 28, 2026 at 4:51 PM
Menarini Group Unveils Promising Data From Elacestrant and Capivasertib Study at ASCO 2026#Italy#Elacestrant#Florence#Menarini_Group#Capivasertib
#oncology #breastcancer #NHS #capivasertib #Truqap #AstraZeneca #targetedtherapy #AKT #AKTinhibitors #ATKKinases #HRpositivebreastcancer #HER2negativebreastcancer #PIK3CAgene #AKT1gene #PTENgene #NICE #NICEguidance #genetictesting #BreastCancerNow
www.bbc.co.uk/news/article...
www.bbc.co.uk/news/article...
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.co.uk
April 11, 2025 at 10:20 AM
Menarini Group Unveils Promising New Findings from ELEVATE Study on Elacestrant and Capivasertib for ER+, HER2- Metastatic Breast Cancer#Italy#Menarini#Elacestrant#Florence#Capivasertib
Menarini Group Unveils Promising New Findings from ELEVATE Study on Elacestrant and Capivasertib for ER+, HER2- Metastatic Breast Cancer
Menarini Group reveals significant data from the ELEVATE clinical study on elacestrant combined with capivasertib for treating ER+, HER2- metastatic breast cancer.
third-news.com
May 29, 2026 at 9:35 AM
Menarini Group Unveils Promising New Findings from ELEVATE Study on Elacestrant and Capivasertib for ER+, HER2- Metastatic Breast Cancer#Italy#Menarini#Elacestrant#Florence#Capivasertib
A new type of drug for one of the most common kinds of advanced breast cancer is now available on the NHS in England.
Find out more about it: bbc.in/4jylHUd
Find out more about it: bbc.in/4jylHUd
Cancer pill 'gave me four years of extra time'
More than 1,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
bbc.in
April 11, 2025 at 10:15 PM
A new type of drug for one of the most common kinds of advanced breast cancer is now available on the NHS in England.
Find out more about it: bbc.in/4jylHUd
Find out more about it: bbc.in/4jylHUd
From leading the discovery of investigational drugs like luminespib and pictilisib to laying the groundwork for approved treatments such as capivasertib, Professor Workman has made major contributions to cancer research and treatment.
Read about Paul's achievements ⤵️
www.icr.ac.uk/about-us/icr...
Read about Paul's achievements ⤵️
www.icr.ac.uk/about-us/icr...
Drug discoverer Paul Workman awarded OBE in New Year’s Honours list
Drug discoverer Paul Workman awarded OBE in New Year’s Honours list
www.icr.ac.uk
December 30, 2025 at 7:55 AM
From leading the discovery of investigational drugs like luminespib and pictilisib to laying the groundwork for approved treatments such as capivasertib, Professor Workman has made major contributions to cancer research and treatment.
Read about Paul's achievements ⤵️
www.icr.ac.uk/about-us/icr...
Read about Paul's achievements ⤵️
www.icr.ac.uk/about-us/icr...
New pill can slow progression of incurable breast cancer
Capivasertib is now available on the NHS in England for advanced breast cancer. It targets a protein molecule that drives cancer growth, doubling the time it takes for the cancer to progress and shrinking tumors in a quarter of patients.
Capivasertib is now available on the NHS in England for advanced breast cancer. It targets a protein molecule that drives cancer growth, doubling the time it takes for the cancer to progress and shrinking tumors in a quarter of patients.
New pill can slow progression of incurable breast cancer - BBC News
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.com
April 10, 2025 at 11:11 PM
New pill can slow progression of incurable breast cancer
Capivasertib is now available on the NHS in England for advanced breast cancer. It targets a protein molecule that drives cancer growth, doubling the time it takes for the cancer to progress and shrinking tumors in a quarter of patients.
Capivasertib is now available on the NHS in England for advanced breast cancer. It targets a protein molecule that drives cancer growth, doubling the time it takes for the cancer to progress and shrinking tumors in a quarter of patients.
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative #BreastCancer: Results from the randomised, global phase III CAPItello-290 trial. www.annalsofoncology.org/article/S092...
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
Adding the pan-AKT inhibitor capivasertib to first-line paclitaxel in metastatic triple-negative
breast cancer (TNBC) led to significantly longer progression-free survival (PFS) and
overall survival (...
www.annalsofoncology.org
January 8, 2026 at 2:34 PM
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative #BreastCancer: Results from the randomised, global phase III CAPItello-290 trial. www.annalsofoncology.org/article/S092...
BBC News - New pill can slow progression of incurable breast cancer
www.bbc.com/news/article...
www.bbc.com/news/article...
New pill can slow progression of incurable breast cancer
Around 3,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.
www.bbc.com
April 11, 2025 at 4:45 AM
BBC News - New pill can slow progression of incurable breast cancer
www.bbc.com/news/article...
www.bbc.com/news/article...
Glycemic Derangements with #Capivasertib—From Hyperglycemia to #DiabeticKetoacidosis: A Report of Three Cases. Read more in #JCEMCaseReports: bit.ly/4n3isFA #InsulinResistance @endocrinesociety.bsky.social
Glycemic Derangements With Capivasertib—From Hyperglycemia to Diabetic Ketoacidosis: A Report of 3 Cases
Abstract. Capiversatib is a pan-Ak strain transforming inhibitor used in combination with fulvestrant for the treatment of hormone receptor-positive advanc
bit.ly
October 24, 2025 at 3:20 PM
Glycemic Derangements with #Capivasertib—From Hyperglycemia to #DiabeticKetoacidosis: A Report of Three Cases. Read more in #JCEMCaseReports: bit.ly/4n3isFA #InsulinResistance @endocrinesociety.bsky.social
4/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 3🏫
CAPItello-291: Capivasertib Side effects
☝️ Rash (12%) onset ~ day 12→ Pretreat with oral antihistamine, topical steroids
💉 Hyperglycemia (18%) onset ~ day 15; ⬇️ G3/G4 than other PIK3CA
📎https://www.esmoopen.com/article/S2059-7029(24)01466-2/fulltext
👩🏻🏫Mini Tweetorial 3🏫
CAPItello-291: Capivasertib Side effects
☝️ Rash (12%) onset ~ day 12→ Pretreat with oral antihistamine, topical steroids
💉 Hyperglycemia (18%) onset ~ day 15; ⬇️ G3/G4 than other PIK3CA
📎https://www.esmoopen.com/article/S2059-7029(24)01466-2/fulltext
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-2...
Capivasertib is a potent, selective pan-AKT inhibitor. In CAPItello-291, the addition
of capivasertib to fulvestrant resulted in a statistically significant (P < 0.001)
improvement in progression-free...
www.esmoopen.com
October 22, 2025 at 12:23 AM
4/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 3🏫
CAPItello-291: Capivasertib Side effects
☝️ Rash (12%) onset ~ day 12→ Pretreat with oral antihistamine, topical steroids
💉 Hyperglycemia (18%) onset ~ day 15; ⬇️ G3/G4 than other PIK3CA
📎https://www.esmoopen.com/article/S2059-7029(24)01466-2/fulltext
👩🏻🏫Mini Tweetorial 3🏫
CAPItello-291: Capivasertib Side effects
☝️ Rash (12%) onset ~ day 12→ Pretreat with oral antihistamine, topical steroids
💉 Hyperglycemia (18%) onset ~ day 15; ⬇️ G3/G4 than other PIK3CA
📎https://www.esmoopen.com/article/S2059-7029(24)01466-2/fulltext
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
📎 pubmed.ncbi.nlm.nih.gov/33246021/
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
📎 pubmed.ncbi.nlm.nih.gov/33246021/
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1 - PubMed
NCT02437318.
pubmed.ncbi.nlm.nih.gov
October 22, 2025 at 12:38 AM
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
📎 pubmed.ncbi.nlm.nih.gov/33246021/
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
📎 pubmed.ncbi.nlm.nih.gov/33246021/
#ESMO25: Promising results w/ capivasertib plus abiraterone from the CAPItello281 #ClinicalTrial in de novo PTEN-deficient metastatic hormone-sensitive #ProstateCancer (#mHSPC) but work needed on accurate quantification of PTEN loss.
#ESMODailyReporter ➡️ https://ow.ly/Uvhb50XeymG
#ESMODailyReporter ➡️ https://ow.ly/Uvhb50XeymG
October 19, 2025 at 8:30 AM
#ESMO25: Promising results w/ capivasertib plus abiraterone from the CAPItello281 #ClinicalTrial in de novo PTEN-deficient metastatic hormone-sensitive #ProstateCancer (#mHSPC) but work needed on accurate quantification of PTEN loss.
#ESMODailyReporter ➡️ https://ow.ly/Uvhb50XeymG
#ESMODailyReporter ➡️ https://ow.ly/Uvhb50XeymG
www.theguardian.com/society/2025...
“Experts hailed the decision as a “landmark moment”. As many as 3,000 women in the UK every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread.”
“Experts hailed the decision as a “landmark moment”. As many as 3,000 women in the UK every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread.”
‘Gamechanging’ breast cancer pill to be offered on NHS in England and Wales
U-turn by medicines watchdog means about 3,000 women with advanced forms of disease could benefit each year
www.theguardian.com
April 10, 2025 at 11:58 PM
www.theguardian.com/society/2025...
“Experts hailed the decision as a “landmark moment”. As many as 3,000 women in the UK every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread.”
“Experts hailed the decision as a “landmark moment”. As many as 3,000 women in the UK every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread.”
Results from trials show that capivasertib plus the hormone therapy fulvestrant increased the time before cancer got worse by about 4.2 months compared with placebo plus fulvestrant – from 3.1 months to 7.3 months.
www.theguardian.com/society/2025...
www.theguardian.com/society/2025...
‘Gamechanging’ breast cancer pill to be offered on NHS in England and Wales
U-turn by medicines watchdog means about 3,000 women with advanced forms of disease could benefit each year
www.theguardian.com
April 11, 2025 at 11:16 AM
Results from trials show that capivasertib plus the hormone therapy fulvestrant increased the time before cancer got worse by about 4.2 months compared with placebo plus fulvestrant – from 3.1 months to 7.3 months.
www.theguardian.com/society/2025...
www.theguardian.com/society/2025...
A story this morning, showing exactly why raising money for research and Breast Cancer Now was so important to me. My link is still open if anyone has any spare pennies.
www.bbc.co.uk/news/article...
www.bbc.co.uk/news/article...
April 11, 2025 at 6:59 AM
A story this morning, showing exactly why raising money for research and Breast Cancer Now was so important to me. My link is still open if anyone has any spare pennies.
www.bbc.co.uk/news/article...
www.bbc.co.uk/news/article...